These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1123 related items for PubMed ID: 9062781

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Serologic responses to measles, mumps, and rubella (MMR) vaccine in healthy infants: failure to respond to measles and mumps components may influence decisions on timing of the second dose of MMR.
    Mitchell LA, Tingle AJ, Décarie D, Lajeunesse C.
    Can J Public Health; 1998; 89(5):325-8. PubMed ID: 9813922
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15-year follow-up in Finland.
    Davidkin I, Peltola H, Leinikki P, Valle M.
    Vaccine; 2000 Jul 15; 18(27):3106-12. PubMed ID: 10856790
    [Abstract] [Full Text] [Related]

  • 46. Immunity to measles before and after MMR booster or primary vaccination at 12 years of age in the first generation offered the 2-dose immunization programme.
    Broliden K, Levén B, Arneborn M, Böttiger M.
    Scand J Infect Dis; 1998 Jul 15; 30(1):23-7. PubMed ID: 9670354
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Administration of measles-mumps-rubella vaccination with other childhood schedule vaccines.
    Heath TC, Burgess MA, O'Brien ED.
    Commun Dis Intell; 1998 Aug 06; 22(8):159. PubMed ID: 9735551
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. [Prevalence of antibodies and vaccination against measles, mumps and rubella in Polish population].
    Janaszek-Seydlitz W, Bucholc B, Wysokińska T, Górska P, Gniadek G.
    Przegl Epidemiol; 2003 Aug 06; 57(2):281-8. PubMed ID: 12910596
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Efficacy and safety of vaccination of marrow transplant recipients with a live attenuated measles, mumps, and rubella vaccine.
    Ljungman P, Fridell E, Lönnqvist B, Bolme P, Böttiger M, Gahrton G, Linde A, Ringdén O, Wahren B.
    J Infect Dis; 1989 Apr 06; 159(4):610-5. PubMed ID: 2647859
    [Abstract] [Full Text] [Related]

  • 59. Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up.
    Davidkin I, Valle M, Julkunen I.
    Vaccine; 1995 Nov 06; 13(16):1617-22. PubMed ID: 8578851
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 57.